SWTX News & Events

SpringWorks Therapeutics announced that long-term efficacy and safety data from the Phase 3 DeFi trial of Ogsiveo, an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the Journal of Clinical Oncology. The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in JCO utilized a December 2024 data cutoff date and showed that longer-term treatment with OGSIVEO was associated with further reductions in tumor size, an increase in objective response rate with additional partial responses and complete responses, sustained improvement in patient reported outcomes, and a consistent safety profile compared to the April 2022 data cut off utilized for the primary analysis of the trial. In the Phase 3 DeFi trial primary analysis, which was previously published in the New England Journal of Medicine, Ogsiveo showed significant improvement versus placebo in progression-free survival, objective response rate and patient-reported outcomes in adult patients with progressing desmoid tumors. In the JCO publication, long-term efficacy and safety were evaluated in patients randomized to Ogsiveo and followed through the final data-cutoff date of December 2024. The median duration of Ogsiveo treatment in these patients was 33.6 months. Objective response rates improved with long-term Ogsiveo treatment. While ORR was 34.3% in year 1, it increased to 45.7% in patients who received Ogsiveo for up to four years, with three additional complete responses and three additional partial responses since the primary analysis and yielding 24 PRs and 8 CRs in total. The median best percent reduction from baseline in target tumor size by RECIST 1.1 with continuous Ogsiveo treatment was -32.3% at year one and -75.8% for patients completing at least four years of treatment. Improvements in patient-reported outcomes of pain, desmoid tumor-specific symptom severity, desmoid tumor-specific physical functioning, global health status/quality of life and role functioning occurred early and were sustained with up to 45 months of treatment with Ogsiveo. Overall, the incidence and severity of frequently reported treatment emergent adverse events decreased through years two, three and four of treatment. The most common adverse events reported in patients receiving Ogsiveo were diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection, and dyspnea.

SpringWorks Therapeutics (SWTX), a healthcare company of Merck KGaA (MKGAY), announced that the European Commission granted marketing authorization for OGSIVEO, an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union to treat desmoid tumors. The EC approval of OGSIVEO is based on results from the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors and met the primary endpoint of improving progression-free survival. OGSIVEO demonstrated a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression. OGSIVEO also demonstrated a significant improvement in objective response rate. The confirmed ORR based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo; the complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. Additionally, OGSIVEO demonstrated early and sustained improvement in patient-reported outcomes, including pain, desmoid tumor-specific symptoms, physical/role functioning, and overall health-related quality of life. OGSIVEO exhibited a manageable safety and tolerability profile. The most common adverse reactions reported in 88 patients receiving OGSIVEO across all studies were diarrhea, rash, ovarian toxicity in women of childbearing potential, nausea, fatigue, hypophosphataemia, headache and stomatitis.

Option delistings effective July 22nd include Radius Recycling, Inc. - Class A Common Stock (RDUS), PHX Minerals Inc. (PHX), LSEA Stock (LSEA), KRON Stock (KRON), Juniper Networks, Inc. (JNPR), INZY Stock (INZY), HARTFORD SCHRODERS COMMODITY STRATEGY ETF (HCOM), EVRI Stock (EVRI), Enstar Group Limited - Ordinary Shares (ESGR), Dada Nexus (DADA), GRANITESHARES 1X SHORT AMD DAILY ETF (AMDS), AGS Stock (AGS), RGLS Stock (RGLS), SWTX Stock (SWTX), WisdomTree Battery Value Chain and Innovation Fund (WBAT), and X Stock (X).

SpringWorks Therapeutics (SWKS), a healthcare company of Merck KGaA (MKGAY), announced today that the European Commission granted conditional marketing authorization for EZMEKLY for the treatment of symptomatic, inoperable plexiform neurofibromas in pediatric and adult patients with neurofibromatosis type 1 aged 2 years and above. EZMEKLY is the first and only therapy approved in the European Union for both adults and children with NF1-PN. The EC approval of EZMEKLY is based on results from the ongoing, multi-center, open-label, single arm Phase 2b ReNeu trial, which enrolled 114 patients with NF1-PN age 2 years or older. The study met the primary endpoint of confirmed objective response rate, as assessed by blinded independent central review, demonstrating an ORR of 41% in adults and 52% in children.